Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small EDRK-rich factor 1B is a small, mostly unstructured, protein encoded by the SERF1B gene on chromosome 5q13. It is a positive regulator of amyloid protein aggregation and proteotoxicity, capable of inducing conformational changes in amyloidogenic proteins such as APP, huntingtin, and alpha-synuclein, thus accelerating their aggregation and potentially contributing to neurodegenerative disease processes. SERF1B is localised to both the cytosol and nucleus and is paralogous to SERF1A. The gene lies in a complex genomic region subject to duplication and rearrangement. Its molecular function is not completely understood, but it has low homology to RNA-binding domains and interacts with protein complexes involved in amyloid fibril formation[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small EDRK-rich factor 1B (SERF1B).